Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-Flash Phase II trial of guanabenz acetate in NAFLD/NASH with hypertension
jRCT2031210380Phase 2Completed
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of guanabenz in metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH) and hypertension (HTN) (2 arms), sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Started Dec 2021; status: completed.
02
Drugs
guanabenz
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)hypertension (HTN)
Beyond the preview
Go deeper on jRCT2031210380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210380.